Search hospitals > New Jersey > Newark
Newark Beth Israel Medical Center
Claim this profileNewark, New Jersey 07112
Global Leader in Breast Cancer
Global Leader in Brain Tumor
Conducts research for Cancer
Conducts research for Leukemia
Conducts research for Lung Cancer
388 reported clinical trials
22 medical researchers
Summary
Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Brain Tumor, Cancer, Leukemia, Lung Cancer and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 540 conditions. There are 22 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Mridula George, MD.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
2Brain Tumor
Global LeaderStage IV
Stage II
Stage I
Top PIs
Teena BhatlaNewark Beth Israel Medical Center6 years of reported clinical research
Studies Burkitt Lymphoma
Studies Leukemia
29 reported clinical trials
69 drugs studied
Howard S. HochsterRutgers Cancer Institute of New Jersey6 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
23 drugs studied
Mridula George, MDRutgers Cancer Institute of New Jersey2 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
14 reported clinical trials
38 drugs studied
Clinical Trials running at Newark Beth Israel Medical Center
Lung Cancer
Breast Cancer
Brain Tumor
Cancer
Testicular cancer
Colon Cancer
Wilms Tumor
Breast cancer
Heart Disease
Heart Failure
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
TRC102 + Chemotherapy/Radiation
for Lung Cancer
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its deoxyribonucleic acid (DNA) and may kill tumor cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC.
Recruiting1 award Phase 224 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Newark Beth Israel Medical Center?
Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Brain Tumor, Cancer, Leukemia, Lung Cancer and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 540 conditions. There are 22 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Mridula George, MD.
Where is Newark Beth Israel Medical Center located?
The Newark Beth Israel Medical Center is located at 201 Lyons Ave, Newark, NJ 07112.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Newark Beth Israel Medical Center, contact the billing department at 973-926-6517. For insurance inquiries, refer to the hospital's phone directory for a dedicated insurance line. Uninsured and underinsured patients meeting specific income and asset criteria may be eligible for the New Jersey Hospital Care Payment Assistance Program (Charity Care).
What insurance does Newark Beth Israel Medical Center accept?
Newark Beth Israel Medical Center, part of RWJBarnabas Health, accepts a wide range of insurance plans including but not limited to Blue Cross/Blue Shield, Commonwealth Care, Harvard Pilgrim Health Care, Neighborhood Health Plan, Mass Health/Medicaid, Medicare, Tufts, and most commercial insurances. They also provide services to patients without insurance. For a detailed list of accepted insurance plans, refer to the RWJBarnabas Health Contracted Health Insurers and Networks list. Note: It's crucial to verify with your physician if they participate in the same insurance plans as the hospital.
What awards or recognition has Newark Beth Israel Medical Center received?
Newark Beth Israel Medical Center is celebrated as one of the World's Best Hospitals by Newsweek for five consecutive years, making it one of seven New Jersey hospitals to achieve this distinction. It has earned the American Heart Association's Get With The Guidelines Gold Award for Heart Failure and Resuscitation. Additionally, it has received the American College of Cardiology's Performance Achievement Award for Cardiac Care.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.